Vaxart Inc (NAS:VXRT)
$ 0.7303 0.0538 (7.95%) Market Cap: 129.57 Mil Enterprise Value: 102.71 Mil PE Ratio: 0 PB Ratio: 2.28 GF Score: 51/100

Vaxart Inc Topline Results Conference Call Transcript

Sep 06, 2023 / 09:00PM GMT
Release Date Price: $0.8 (-4.05%)
Operator

Greetings and welcome to the Vaxart monovalent norovirus challenge study top line results conference call.

(Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the webcast over to your host, Ed Berg, Senior Vice President and General Counsel.

Edward B. Berg
Vaxart, Inc. - Senior VP & General Counsel

Good afternoon and welcome to today's call.

Joining us from Vaxart are Andrei Floroiu, Chief Executive Officer; Dr. Sean Tucker, Founder and Chief Scientific Officer; and Dr. James Cummings, Chief Medical Officer.

Before we get started, I would like to remind everyone that, during this conference call, Vaxart may make forward-looking statements, including statements about the company's financial results; financial guidance; its future business strategies and operations; and its product development and regulatory progress, including statements about its ongoing or planned clinical trials. Actual results could differ materially from those discussed in these forward-looking statements due

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot